HAE

SEC source: 0001127602-21-017682 · form4.xml · nonDerivative · entry 1

Lingamneni Anila · CIK 0001808414 · EVP, Chief Technology Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,224

F1 · kind: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest in annual increments of 25% beginning on the first anniversary of the date of grant.

F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest in annual increments of 25% beginning on the first anniversary of the date of grant.

F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

F3 · balance_after: This number includes unvested RSUs previously reported as well as 245 shares acquired by the reporting person under the Issuer's 2007 Employee Stock Purchase Plan (as amended) on April 30, 2021.

SEC source: 0001127602-21-017681 · form4.xml · derivative · entry 4

Llorens Josep · CIK 0001750812 · SVP, Global Manufacturing

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,564

Underlying: Common Stock · 9,564 shares

Expires 2028-05-18

F6 · derivative.exercise_date: Option vests in annual increments of 25% beginning on the first anniversary of the date of grant.

SEC source: 0001127602-21-017681 · form4.xml · nonDerivative · entry 2

Llorens Josep · CIK 0001750812 · SVP, Global Manufacturing

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,745

F4 · kind: The securities awarded are in the form of RSUs issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest in annual increments of 50% beginning on the first anniversary of the date of grant.

F4 · shares: The securities awarded are in the form of RSUs issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest in annual increments of 50% beginning on the first anniversary of the date of grant.

F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

F3 · balance_after: This number includes unvested RSUs previously reported.

SEC source: 0001127602-21-017681 · form4.xml · nonDerivative · entry 1

Llorens Josep · CIK 0001750812 · SVP, Global Manufacturing

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,675

F1 · kind: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest in annual increments of 25% beginning on the first anniversary of the date of grant.

F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest in annual increments of 25% beginning on the first anniversary of the date of grant.

F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

F3 · balance_after: This number includes unvested RSUs previously reported.

SEC source: 0001127602-21-017680 · form4.xml · derivative · entry 4

Basil Michelle L · CIK 0001699629 · EVP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,737

Underlying: Common Stock · 16,737 shares

Expires 2028-05-18

F6 · derivative.exercise_date: Option vests in annual increments of 25% beginning on the first anniversary of the date of grant.

SEC source: 0001127602-21-017680 · form4.xml · nonDerivative · entry 2

Basil Michelle L · CIK 0001699629 · EVP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 39,267

F4 · kind: The securities awarded are in the form of RSUs issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest in annual increments of 50% beginning on the first anniversary of the date of grant.

F4 · shares: The securities awarded are in the form of RSUs issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest in annual increments of 50% beginning on the first anniversary of the date of grant.

F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

F3 · balance_after: This number includes unvested RSUs previously reported.

SEC source: 0001127602-21-017680 · form4.xml · nonDerivative · entry 1

Basil Michelle L · CIK 0001699629 · EVP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,590

F1 · kind: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest in annual increments of 25% beginning on the first anniversary of the date of grant.

F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest in annual increments of 25% beginning on the first anniversary of the date of grant.

F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

F3 · balance_after: This number includes unvested RSUs previously reported.

SEC source: 0001127602-21-017677 · form4.xml · derivative · entry 4

Burke William P. Mr. · CIK 0001682069 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,933

Underlying: Common Stock · 17,933 shares

Expires 2028-05-18

F6 · derivative.exercise_date: Option vests in annual increments of 25% beginning on the first anniversary of the date of grant.

SEC source: 0001127602-21-017677 · form4.xml · nonDerivative · entry 2

Burke William P. Mr. · CIK 0001682069 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,423

F4 · kind: The securities awarded are in the form of RSUs issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest in annual increments of 50% beginning on the first anniversary of the date of grant.

F4 · shares: The securities awarded are in the form of RSUs issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest in annual increments of 50% beginning on the first anniversary of the date of grant.

F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

F3 · balance_after: This number includes unvested RSUs previously reported.

SEC source: 0001127602-21-017677 · form4.xml · nonDerivative · entry 1

Burke William P. Mr. · CIK 0001682069 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,746

F1 · kind: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest in annual increments of 25% beginning on the first anniversary of the date of grant.

F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest in annual increments of 25% beginning on the first anniversary of the date of grant.

F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

F3 · balance_after: This number includes unvested RSUs previously reported.

SEC source: 0001127602-21-017675 · form4.xml · derivative · entry 3

Simon, Christopher · CIK 0001674993 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 71,733

Underlying: Common Stock · 71,733 shares

Expires 2028-05-18

F5 · derivative.exercise_date: Option vests in annual increments of 25% beginning on the first anniversary of the date of grant.

SEC source: 0001127602-21-017675 · form4.xml · nonDerivative · entry 1

Simon, Christopher · CIK 0001674993 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 196,745

F1 · kind: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest in annual increments of 25% beginning on the first anniversary of the date of grant.

F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest in annual increments of 25% beginning on the first anniversary of the date of grant.

F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

F3 · balance_after: This number includes unvested RSUs previously reported.

SEC source: 0001127602-21-017271 · form4.xml · nonDerivative · entry 1

Llorens Josep · CIK 0001750812 · SVP, Global Manufacturing

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,140

F1 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F2 · balance_after: This number includes unvested RSUs previously reported.

SEC source: 0001127602-21-017273 · form4.xml · nonDerivative · entry 1

Goldstein Dan · CIK 0001722327 · VP, Corporate Controller

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,469

F1 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F2 · balance_after: This number includes unvested RSUs previously reported.

SEC source: 0001127602-21-017269 · form4.xml · nonDerivative · entry 1

Scanlan Jacqueline · CIK 0001713517 · SVP, Global Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,523

F1 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F2 · balance_after: This number includes unvested RSUs previously reported as well as 245 shares acquired by the reporting person under the Issuer's 2007 Employee Stock Purchase Plan (as amended) on April 30, 2021.

SEC source: 0001127602-21-017257 · form4.xml · nonDerivative · entry 1

Burke William P. Mr. · CIK 0001682069 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,118

F1 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F2 · balance_after: This number includes unvested RSUs previously reported.

SEC source: 0001127602-21-017263 · form4.xml · nonDerivative · entry 1

Basil Michelle L · CIK 0001699629 · EVP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,403

F1 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F2 · balance_after: This number includes unvested RSUs previously reported.

SEC source: 0001127602-21-017256 · form4.xml · nonDerivative · entry 1

Simon, Christopher · CIK 0001674993 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 170,230

F1 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F2 · balance_after: This number includes unvested RSUs previously reported as well as 245 shares acquired by the reporting person under the Issuer's 2007 Employee Stock Purchase Plan (as amended) on April 30, 2021.

SEC source: 0001127602-21-014117 · form4.xml · nonDerivative · entry 1

Lingamneni Anila · CIK 0001808414 · EVP, Chief Technology Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,444

F1 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2019 Long Term Incentive Compensation Plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2019 Long Term Incentive Compensation Plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F2 · balance_after: This number includes unvested RSUs and 224 shares purchased by the reporting person under the Issuer's 2007 Employee Stock Purchase Plan (as amended) on October 30, 2020.

SEC source: 0001127602-21-010074 · form4.xml · nonDerivative · entry 1

Scanlan Jacqueline · CIK 0001713517 · SVP, Global Human Resources

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,380

F1 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2019 Long Term Incentive Compensation Plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2019 Long Term Incentive Compensation Plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F2 · balance_after: This number includes unvested RSUs previously reported.

SEC source: 0001127602-21-010073 · form4.xml · nonDerivative · entry 1

Basil Michelle L · CIK 0001699629 · EVP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,607

F1 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2019 Long Term Incentive Compensation Plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2019 Long Term Incentive Compensation Plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F2 · balance_after: This number includes unvested RSUs previously reported.

SEC source: 0001127602-21-004202 · form4.xml · derivative · entry 3

MEELIA RICHARD J · CIK 0001223633 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 10,353 shares

Expires 2021-07-23

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reporting person exercised options that were granted in 2014 and scheduled to expire on July 23, 2021, as reflected in this Form 4.

F4 · derivative.exercise_date: Options vest 100% on the first anniversary of the date of grant.

SEC source: 0001127602-21-004202 · form4.xml · nonDerivative · entry 2

MEELIA RICHARD J · CIK 0001223633 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,050

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $134.39 to $135.30, inclusive. The reporting person undertakes to provide to Haemonetics Corporation ("Haemonetics"), any security holder of Haemonetics, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F2 · balance_after: This number includes unvested restricted stock units previously reported.

SEC source: 0001127602-21-004202 · form4.xml · nonDerivative · entry 1

MEELIA RICHARD J · CIK 0001223633 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 42,403

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reporting person exercised options that were granted in 2014 and scheduled to expire on July 23, 2021, as reflected in this Form 4.

F2 · balance_after: This number includes unvested restricted stock units previously reported.

SEC source: 0001127602-21-004193 · form4.xml · derivative · entry 4

Dockendorff Charles J · CIK 0001400563 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 12,180 shares

Expires 2021-07-23

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reporting person exercised options that were granted in 2014 and scheduled to expire on July 23, 2021, as reflected in this Form 4.

F5 · derivative.exercise_date: Options vest 100% on the first anniversary of the date of grant.

SEC source: 0001127602-21-004193 · form4.xml · nonDerivative · entry 2

Dockendorff Charles J · CIK 0001400563 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,755

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $134.14 to $135.00, inclusive. The reporting person undertakes to provide to Haemonetics Corporation ("Haemonetics"), any security holder of Haemonetics, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F2 · balance_after: This number includes unvested restricted stock units previously reported.

SEC source: 0001127602-21-004193 · form4.xml · nonDerivative · entry 1

Dockendorff Charles J · CIK 0001400563 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,935

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The reporting person exercised options that were granted in 2014 and scheduled to expire on July 23, 2021, as reflected in this Form 4.

F2 · balance_after: This number includes unvested restricted stock units previously reported.

SEC source: 0001127602-21-004183 · form4.xml · derivative · entry 10

Goldstein Dan · CIK 0001722327 · VP, Corporate Controller

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,503

Underlying: Common Stock · 500 shares

Expires 2026-05-14

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: Option vests in annual increments of 25% beginning on the first anniversary of the date of grant.

SEC source: 0001127602-21-004183 · form4.xml · derivative · entry 9

Goldstein Dan · CIK 0001722327 · VP, Corporate Controller

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 952

Underlying: Common Stock · 476 shares

Expires 2025-06-11

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: Option vests in annual increments of 25% beginning on the first anniversary of the date of grant.

SEC source: 0001127602-21-004183 · form4.xml · derivative · entry 8

Goldstein Dan · CIK 0001722327 · VP, Corporate Controller

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,457 shares

Expires 2023-10-25

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: Option vests in annual increments of 25% beginning on the first anniversary of the date of grant.

SEC source: 0001127602-21-004183 · form4.xml · nonDerivative · entry 7

Goldstein Dan · CIK 0001722327 · VP, Corporate Controller

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,511

F1 · balance_after: This number includes unvested restricted stock units previously reported.

SEC source: 0001127602-21-004183 · form4.xml · nonDerivative · entry 6

Goldstein Dan · CIK 0001722327 · VP, Corporate Controller

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,749

F1 · balance_after: This number includes unvested restricted stock units previously reported.

SEC source: 0001127602-21-004183 · form4.xml · nonDerivative · entry 5

Goldstein Dan · CIK 0001722327 · VP, Corporate Controller

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,249

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: This number includes unvested restricted stock units previously reported.

SEC source: 0001127602-21-004183 · form4.xml · nonDerivative · entry 4

Goldstein Dan · CIK 0001722327 · VP, Corporate Controller

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,749

F1 · balance_after: This number includes unvested restricted stock units previously reported.

SEC source: 0001127602-21-004183 · form4.xml · nonDerivative · entry 3

Goldstein Dan · CIK 0001722327 · VP, Corporate Controller

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,225

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: This number includes unvested restricted stock units previously reported.

SEC source: 0001127602-21-004183 · form4.xml · nonDerivative · entry 2

Goldstein Dan · CIK 0001722327 · VP, Corporate Controller

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,749

F1 · balance_after: This number includes unvested restricted stock units previously reported.

SEC source: 0001127602-21-004183 · form4.xml · nonDerivative · entry 1

Goldstein Dan · CIK 0001722327 · VP, Corporate Controller

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,206

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: This number includes unvested restricted stock units previously reported.

SEC source: 0001127602-20-031192 · form4.xml · nonDerivative · entry 1

Simon, Christopher · CIK 0001674993 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 170,941

F1 · kind: These securities were transferred by the reporting person as a gift without any consideration to the Simon Family 2020 Irrevocable Trust for the benefit of the reporting person's children, which trust has an independent trustee.

F2 · balance_after: This number includes unvested restricted stock units previously reported.

SEC source: 0001127602-20-027619 · form4.xml · nonDerivative · entry 1

Burke William P. Mr. · CIK 0001682069 · EVP, Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,337

F1 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F2 · balance_after: This number includes unvested RSUs previously reported.

SEC source: 0001127602-20-027621 · form4.xml · nonDerivative · entry 1

Goldstein Dan · CIK 0001722327 · VP, Corporate Controller

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,749

F1 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F2 · balance_after: This number includes unvested RSUs previously reported.

SEC source: 0001127602-20-027525 · form4.xml · nonDerivative · entry 1

Basil Michelle L · CIK 0001699629 · EVP and General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,992

F1 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2019 Long Term Incentive Compensation Plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2019 Long Term Incentive Compensation Plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F2 · balance_after: This number includes unvested RSUs previously reported.

SEC source: 0001127602-21-016857 · form5.xml · nonDerivative · entry 2

KROLL MARK W · CIK 0001259254 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,900

F1 · kind: Shares transferred as a bona fide gift without any consideration.

F2 · balance_after: This number includes unvested restricted stock units previously reported.

SEC source: 0001127602-21-016857 · form5.xml · nonDerivative · entry 1

KROLL MARK W · CIK 0001259254 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,067

F1 · kind: Shares transferred as a bona fide gift without any consideration.

F2 · balance_after: This number includes unvested restricted stock units previously reported.

SEC source: 0001127602-20-024912 · form4.xml · nonDerivative · entry 1

Llorens Josep · CIK 0001750812 · SVP, Global Manufacturing

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,254

F1 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain restricted stock units ("RSUs") previously reported in Table I following the date of grant. This sale is mandated by the Issuer's election under its 2005 Long Term Incentive Compensation Plan (as amended) to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

F2 · balance_after: This number includes unvested RSUs previously reported.

SEC source: 0001127602-20-023469 · form4.xml · nonDerivative · entry 1

ABERNATHY ROBERT E · CIK 0001222888 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,048

F1 · balance_after: This number includes unvested restricted stock units previously reported.

SEC source: 0001127602-20-021997 · form4.xml · nonDerivative · entry 1

Zane Ellen M · CIK 0001369850 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,440

F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant.

F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

F3 · balance_after: This number includes unvested RSUs previously reported.

SEC source: 0001127602-20-021993 · form4.xml · nonDerivative · entry 1

Pomeroy Claire · CIK 0001603648 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,939

F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant.

F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

F3 · balance_after: This number includes unvested RSUs previously reported.

SEC source: 0001127602-20-021988 · form4.xml · nonDerivative · entry 1

MEELIA RICHARD J · CIK 0001223633 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,050

F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant.

F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

F3 · balance_after: This number includes unvested RSUs previously reported.

SEC source: 0001127602-20-021981 · form4.xml · nonDerivative · entry 1

KROLL MARK W · CIK 0001259254 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,401

F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant.

F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

F3 · balance_after: This number includes unvested RSUs previously reported.

SEC source: 0001127602-20-021979 · form4.xml · nonDerivative · entry 1

Dockendorff Charles J · CIK 0001400563 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,755

F1 · shares: The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant.

F2 · price: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

F3 · balance_after: This number includes unvested RSUs previously reported.